logo
  

ITC Holdings Announces New 5-Yr Plan, $250 Mln Stock Buyback Program

ITC Holdings Corp. (ITC) on Tuesday announced its new five-year capital investment plan of about $4.5 billion for the period 2014 through 2018, as a part of a comprehensive strategic update.

The new five-year plan reflects expected investments of about $2.2 billion in ITC's base operating companies, about $1.2 billion in regional infrastructure projects, and about $1.1 billion in additional development projects.

The company expects successful execution of the capital investment plan to increase its consolidated year-end rate base plus construction work in progress by about 70% over the plan period. The increase in projected rate base plus construction work in progress is expected to result in compound annual growth in operating earnings per share in the range of 11% to 13% over the forecast period.

The company also said it expects to grow its dividend annually in the range of 10% to 15% over the same time frame.

Additionally, the company said its board of directors has authorized up to $250 million in share repurchases through December 31, 2015 as part of its broader capital allocation plan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT